In addition, we observed that upregulation of these proteins in the blood-derived EVs seems to correlate with clinical benefit that a pilot cohort of breast cancer patients with metastatic ErbB2-positive tumors received from trastuzumab-based therapies. Here, ERBB2 is linked to breast carcinoma.